Regeneron’s trial fails to reach statistical significance for primary endpoint

Regeneron Pharmaceuticals has reported that its Phase III trial assessing fianlimab and cemiplimab for metastatic melanoma failed to reach statistical significance for the primary endpoint. The double-blind, randomised trial tested two dosing regimens against a pembrolizumab monotherapy. The trial enrolled 1,546 participants with previously untreated, unresectable locally advanced or metastatic melanoma. Credit: Green Apple / Shutterstock.com. Regeneron Pharmaceuticals has reported that its Phase III trial assessing fianlimab (a LAG-3 inhibitor) and cemiplimab (a PD-1 inhibitor) for metastatic melanoma failed to reach statistical significance for the primary endpoint. This combination is evaluated as a first-line treatment for patients with unresectable locally…

Source: Clinical Trials Arena